Skip to content
Nonprofiteer
← EVERSIGHT

Form 990 for tax year 2022

Filed by EVERSIGHT.

Totals

Total revenue
$25,488,101
Total expenses
$24,016,038
Contributions and grants received
$864,304
Grants paid
$0
Program service revenue
$24,444,041
Investment income
$134,853
Other revenue
$44,903
Total assets, end of year
$41,527,985
Total liabilities, end of year
$22,776,198
Net assets or fund balances, end of year
$18,751,787
Program services expenses (Part IX)
$18,358,717
Management and general expenses
$5,140,936
Fundraising expenses
$516,385
Program service expenses (Part III)
$18,358,717

Program services were 76.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $183,952

  • 1f · All other contributions, gifts and grants

    $680,352

  • 1g · Noncash contributions included above

    $63,120

  • 2a · Program service revenue: EYE TISSUE FEES

    total $22,401,703 · related or exempt $22,401,703

  • 2b · Program service revenue: INTERCOMPANY CHARGES

    total $1,976,155 · related or exempt $1,976,155

  • 2c · Program service revenue: OTHER REVENUE

    total $66,183 · related or exempt $66,183

  • 3 · Investment income

    total $181,255 · excluded $181,255

  • 7a · Gross sales of assets other than inventory

    securities $4,415,128

  • 7b · Less cost or other basis and sales expenses

    securities $4,461,530

  • 7c · Gain or loss

    securities -$46,402

  • 7d · Net gain or loss

    total -$46,402 · excluded -$46,402

  • 8a · Fundraising events: gross income

    $173,526

  • 8a · Fundraising events: contributions included on line 1c

    $183,952

  • 8b · Fundraising events: direct expenses

    $128,623

  • 8c · Net income from fundraising events

    total $44,903 · excluded $44,903

Functional expenses

Part IX, the statement of functional expenses.

  • 5 · Compensation of officers, directors and key employees

    total $1,273,852 · program services $260,534 · management and general $1,013,318

  • 7 · Other salaries and wages

    total $8,837,386 · program services $6,363,225 · management and general $2,215,882 · fundraising $258,279

  • 8 · Pension plan contributions

    total $485,301 · program services $354,571 · management and general $116,254 · fundraising $14,476

  • 9 · Other employee benefits

    total $1,223,315 · program services $912,690 · management and general $273,140 · fundraising $37,485

  • 10 · Payroll taxes

    total $826,584 · program services $551,833 · management and general $253,055 · fundraising $21,696

  • 11b · Fees: legal

    total $10,306 · management and general $10,306

  • 11c · Fees: accounting

    total $42,675 · management and general $42,675

  • 11f · Fees: investment management

    total $81,101 · management and general $81,101

  • 11g · Fees: other

    total $315,717 · program services $190,492 · management and general $125,225

  • 13 · Office expenses

    total $220,430 · program services $163,876 · management and general $46,371 · fundraising $10,183

  • 14 · Information technology

    total $204,802 · program services $152,867 · management and general $44,402 · fundraising $7,533

  • 16 · Occupancy

    total $1,385,437 · program services $1,029,457 · management and general $303,244 · fundraising $52,736

  • 17 · Travel

    total $160,589 · program services $111,997 · management and general $40,409 · fundraising $8,183

  • 19 · Conferences, conventions and meetings

    total $94,036 · program services $37,005 · management and general $48,919 · fundraising $8,112

  • 22 · Depreciation, depletion and amortization

    total $238,232 · program services $176,371 · management and general $52,648 · fundraising $9,213

  • 23 · Insurance

    total $344,417 · program services $261,621 · management and general $71,541 · fundraising $11,255

  • 24a · Other expenses: CLINICAL LAB & TECH EXP

    total $7,412,904 · program services $7,412,904

  • 24b · Other expenses: MISCELLANEOUS

    total $314,561 · program services $5,259 · management and general $307,543 · fundraising $1,759

  • 24c · Other expenses: MEMBERSHIP DUES

    total $174,578 · program services $174,578

  • 24d · Other expenses: BUSINESS DEVELOPMENT

    total $126,094 · program services $30,230 · management and general $94,903 · fundraising $961

  • 24e · All other expenses

    total $243,721 · program services $169,207 · fundraising $74,514

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $7,492,551 · end of year $2,483,366

  • 2 · Savings and temporary cash investments

    beginning of year $175,878 · end of year $5,263,160

  • 3 · Pledges and grants receivable

    beginning of year $13,500

  • 4 · Accounts receivable

    beginning of year $2,743,326 · end of year $2,930,442

  • 9 · Prepaid expenses and deferred charges

    beginning of year $111,107 · end of year $157,170

  • 10a · Land, buildings and equipment: cost or other basis

    $15,986,576

  • 10b · Land, buildings and equipment: accumulated depreciation

    $7,881,308

  • 10c · Land, buildings and equipment, net

    beginning of year $8,148,086 · end of year $8,105,268

  • 11 · Investments: publicly traded securities

    beginning of year $9,769,850 · end of year $9,147,484

  • 15 · Other assets

    beginning of year $12,861,199 · end of year $13,441,095

  • 17 · Accounts payable and accrued expenses

    beginning of year $1,843,013 · end of year $1,901,749

  • 19 · Deferred revenue

    beginning of year $400 · end of year $400

  • 24 · Unsecured notes and loans payable

    beginning of year $7,549,199 · end of year $7,059,250

  • 25 · Other liabilities

    beginning of year $12,553,428 · end of year $13,814,799

  • 27 · Net assets without donor restrictions

    beginning of year $19,018,819 · end of year $18,606,591

  • 28 · Net assets with donor restrictions

    beginning of year $350,638 · end of year $145,196

Mission and programs · 2022

Mission

EVERSIGHT'S MISSION IS TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. BLINDING EYE DISEASES AFFECT 80 MILLION AMERICANS. THAT MEANS MILLIONS OF PEOPLE CANNOT SEE THEIR LOVED ONES, DRIVE TO WORK OR READ THE NEWSPAPER ON A SUNDAY MORNING. THEIR VISION LOSS RESULTS IN AN ECONOMIC IMPACT OF 51.4 BILLION EVERY YEAR IN THE UNITED STATES ALONE. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL MOTHERS CAN SEE THEIR CHILDREN AND ALL CHILDREN CAN GROW UP TO LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. TO MAKE VISION A REALITY FOR ALL, EVERSIGHT CONTINUOUSLY WORKS TO EXPAND ITS REACH, CONNECT MORE EFFECTIVELY WITH COMMUNITIES IN NEED AND PROVIDE THE GIFT OF SIGHT TO EVERYONE.

Activities or mission (Part I)

EVERSIGHT IS A 501(C)3 NONPROFIT ORGANIZATION WITH THE MISSION TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. THE EVERSIGHT NETWORK IS RESPONSIBLE FOR RECOVERING, EVALUATING AND PROVIDING HUMAN EYE TISSUE FOR TRANSPLANTATION; ADVANCING RESEARCH INTO THE CAUSES AND CURES OF BLINDING EYE CONDITIONS; PROMOTING DONATION AWARENESS THROUGH PUBLIC AND PROFESSIONAL EDUCATION; AND PROVIDING HUMANITARIAN AID TO PEOPLE AROUND THE WORLD IN NEED OF CORNEAL TRANSPLANTATION. FOUNDED IN 1947, EVERSIGHT MAINTAINS ITS COMMITMENT TO EXCELLENCE AS AN ACCREDITED MEMBER OF THE EYE BANK ASSOCIATION OF AMERICA (EBAA) AND BY MEETING THE HIGHEST QUALITY STANDARDS SET BY THE U.S. FOOD AND DRUG ADMINISTRATION. THE NONPROFIT OPERATES 24/7/365 IN CONNECTICUT, ILLINOIS, MICHIGAN, NEW JERSEY, OHIO AND SOUTH KOREA, AND COLLABORATES WITH SURGEONS, RESEARCHERS, ACADEMIC MEDICAL CENTERS AND EYE BANKS ACROSS THE UNITED STATES AND ABROAD. EVERSIGHT WORKS WITH THE

  • RESORING SIGHT IN 2022, EVERSIGHT CELEBRATED ITS 75TH ANNIVERSARY. WE OVERCAME SEVERAL UNFORESEEN CHALLENGES THIS YEAR AND CONTINUED TO MEET THE TISSUE DEMANDS OF SURGEONS IN THE U.S. AND BEYOND. GLOBALLY, WE CONTINUE TO TAKE MEANINGFUL STEPS TOWARD TRANSFORMING THE FUTURE OF VISION CARE BY SUPPORTING SUSTAINABLE EYE BANKING INFRASTRUCTURE AND PROVIDING PRICELESS CLINICAL EDUCATION. IN 2022, EVERSIGHT PROVIDED THE GIFT OF SIGHT TO MORE THAN 6,500 PEOPLE ACROSS THE UNITED STATES AND AROUND THE WORLD. EVERSIGHT'S WORK BEGAN IN 1947 WITH THE ESTABLISHMENT OF THE FOURTH EYE BANK IN THE UNITED STATES, THEN KNOWN AS THE ILLINOIS EYE-BANK. OVER TIME, NONPROFIT EYE BANKS WERE ESTABLISHED IN EVERY STATE TO MEET THE CRITICAL DEMAND FOR CORNEAL TISSUE TO TREAT PREVENTABLE BLINDNESS. IN 1985, THE ILLINOIS EYE-BANK AND MICHIGAN EYE-BANK FORMED A PARTNERSHIP ONE THAT WOULD EARN A REPUTATION FOR CLINICAL EXCELLENCE MADE POSSIBLE BY SOME OF THE FINEST MEDICAL DIRECTORS, STAFF AND BOARD MEMBERS IN THE EYE BANKING FIELD. THE SUCCESS OF THE ORGANIZATION ATTRACTED AFFILIATIONS WITH OTHER REGIONAL EYE BANKS FORMING ONE OF THE LARGEST NETWORKS OF EYE BANKS IN THE U.S. IN 2015, THE NETWORK BECAME KNOWN AS EVERSIGHT, ALL WORKING TOGETHER AS A UNIFIED OPERATION TO DELIVER THE HIGHEST QUALITY SERVICES TO SURGEONS AND THEIR PATIENTS AND TO CONTINUE TO GROW OUR IMPACT AROUND THE WORLD. IN 2022, EVERSIGHT FACED AN UNPRECEDENTED CHALLENGE IN THE FORM OF A CORNEA STORAGE MEDIA SHORTAGE. CORNEA STORAGE MEDIA IS THE SOLUTION IN WHICH CORNEAS ARE STORED BETWEEN RECOVERY AND TRANSPLANTATION. THIS SHORTAGE IMPACTS EVERSIGHT'S ABILITY TO STORE REQUESTED TISSUE. EVERSIGHT PRIORITIZES THE PLACEMENT OF DONATED TISSUE DOMESTICALLY. AS SUCH, THIS STORAGE MEDIA SHORTAGE IMPACTED OUR ABILITY TO PLACE TISSUE INTERNATIONALLY, FOR RESEARCH AND FOR EDUCATION. TO ADDRESS THIS CHALLENGE, EVERSIGHT STAFF COLLABORATED WITH DOMESTIC EYE BANK PARTNERS TO SHARE STORAGE MEDIA AND ENSURE THE PROPER SUPPLY OF DONATED CORNEA TISSUES. THESE PARTNERSHIPS ALLOWED US TO MEET THE NEED FOR CORNEA TISSUE IN THE U.S. AND ABROAD. EVERSIGHT PROVIDED 11,676 TISSUES FOR TRANSPLANTATION, RESEARCH AND EDUCATION GLOBALLY IN 2022. WE WORKED OR PLACED TISSUE WITH PHYSICIANS AND RESEARCHERS IN 32 COUNTRIES AND FACILITATED TRAINING FOR OVER 550 CLINICIANS. TOGETHER WITH ALL OUR PARTNERS-ADVOCATES, DONOR FAMILIES, TRANSPLANT RECIPIENTS, SURGEONS, LIONS, FELLOW EYE BANKS, HEALTHCARE LEADERS, PHILANTHROPIC SUPPORTERS AND MANY OTHERS-WE WERE ABLE TO MAKE VISION A REALITY FOR MORE PEOPLE WORLDWIDE.

    Expenses $16,971,336 · Revenue $24,368,324

  • FINDING A CURE IN THE PURSUIT OF ELIMINATING BLINDING EYE DISEASES, EVERSIGHT ESTABLISHED THE EVERSIGHT CENTER FOR VISION AND EYE BANKING RESEARCH IN CLEVELAND, OHIO, TO PROVIDE LEADING OPHTHALMOLOGY RESEARCHERS WITH THE RESOURCES THEY NEED TO FIND CURES AND TREATMENTS FOR EYE DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND GLAUCOMA. EVERSIGHT PROVIDED MORE THAN 3,900 TISSUES FOR RESEARCH AND EDUCATION PURPOSES IN 2022. OUR IN-HOUSE RESEARCH TEAM ALSO PROVIDED EVERSIGHT PARTNERS WITH VALUABLE RESEARCH AND DEVELOPMENT SERVICES, AND PIONEERED NEW EYE BANKING PRACTICES. SINCE THE ESTABLISHMENT OF THE CENTER FOR VISION AND EYE BANKING RESEARCH IN 2019, EVERSIGHT HAS PUBLISHED 20 SCIENTIFIC PUBLICATIONS IN PEER REVIEWED SCIENTIFIC JOURNALS. NOTABLY, IN 2022, EVERSIGHT'S RESEARCH TEAM PUBLISHED THREE HIGHLY SIGNIFICANT AND IMPACTFUL RESEARCH ARTICLES. THE FIRST FOCUSED ON UNDERSTANDING THE EFFECT OF INCREASING POVIDONE-IODINE EXPOSURE ON CORNEAL TISSUE AND ITS IMPACT ON THE GROWTH OF MICROORGANISMS. THIS RESEARCH CONDUCTED BY EVERSIGHT DEVELOPED AN INNOVATIVE PROTOCOL FOR ALL OTHER EYE BANKS TO FOLLOW THAT CAN IMPROVE OUTCOMES FOR CORNEAL TRANSPLANT RECIPIENTS AND REDUCE RISK OF INFECTION AFTER CORNEAL TRANSPLANTATION. THE SECOND STUDY, PUBLISHED IN THE PRESTIGIOUS AND HIGH-IMPACT FACTOR JOURNAL, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, DISCOVERED THE IMPORTANT BIOLOGICAL PROCESS OF VISUAL PHOTOTRANSDUCTION IN THE RETINA COLLECTED FROM CADAVERIC HUMAN TISSUE PROCURED AND PROCESSED BY EVERSIGHT. THIS STUDY ALLOWED EVERSIGHT'S RESEARCH TEAM TO GAIN ADDITIONAL RECOGNITION AMONG OUR PEERS AS A LEADING RESEARCH-DRIVEN EYE BANK. THIS WORK SERVES AS AN EXAMPLE TO THE OPHTHALMIC RESEARCH INDUSTRY THAT CADAVERIC OCULAR TISSUES PLAY AN IMPORTANT ROLE IN UNDERSTANDING THE PHYSIOLOGY AND PATHOLOGY OF VARIOUS OPHTHALMIC DISEASES AND THE VISUAL PHOTO- TRANSDUCTION PROCESS. THE FINAL STUDY REVEALED HISTOPATHOLOGICAL ASSESSMENT OF RETINAL BLOOD VESSEL CHANGES IN A PATIENT WITH COVID-19, PROVIDING A DEEPER UNDERSTANDING OF THE IMPACT OF COVID-19 ON THE RETINA. THIS STUDY WAS PUBLISHED IN THE JOURNAL, GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY. EVERSIGHT HAS A LONGSTANDING TRACK RECORD OF RESEARCH AND DEVELOPMENT, HAVING AWARDING MORE THAN 4 MILLION IN GRANTS TO DATE THAT STIMULATE PIONEERING CLINICAL AND BASIC SCIENCE RESEARCH AIMING TO DEVELOP NEW WAYS TO RESTORE SIGHT, PREVENT BLINDNESS AND ULTIMATELY HELP PATIENTS LIVE LIFE TO THE FULLEST. SINCE 1980, OUR EYE & VISION RESEARCH GRANT PROGRAM HAS SUPPORTED RESEARCHERS AT LEADING ACADEMIC MEDICAL INSTITUTIONS INCLUDING HARVARD, TUFTS, CLEVELAND CLINIC, CASE WESTERN RESERVE, UNIVERSITY OF MICHIGAN, NORTHWESTERN AND MORE. BY DESIGN, EVERSIGHT'S GRANT PROGRAM PROVIDES CRITICAL, EARLY-STAGE FUNDING THAT IS INTENDED TO DRIVE FOUNDATIONAL RESEARCH AND DISCOVERY. MANY OF THESE PROJECTS HAVE STIMULATED LARGER-SCALE STUDIES AND WON FURTHER FINANCIAL SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH. IN THE 2023 FUNDING CYCLE, EVERSIGHT AWARDED GRANTS TO ADVANCE STUDIES TO ENHANCE THE OVERALL UNDERSTANDING OF THE MECHANISMS UNDERLYING DELAYED EPITHELIAL WOUND HEALING IN DIABETIC CORNEAS; CREATE SAFER PROCEDURES FOR SUCCESSFUL CORNEAL TRANSPLANTS; ELUCIDATE THE POTENCY OF NETRIN-4 TO INDUCE NEURONAL GROWTH, ELONGATION AND BRANCHING; AND ESTABLISH THE FOUNDATIONS FOR FUTURE STUDIES TO DEFINE THE ROLES OF POLYQ PROTEINS IN THE HUMAN EYE. THESE INVESTIGATIONS ARE LED BY RESEARCHERS AT WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE, UNIVERSITY OF MICHIGAN KELLOGG EYE CENTER, CASE WESTERN RESERVE UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY & VISUAL SCIENCES, AND UNIVERSITY OF ILLINOIS-CHICAGO COLLEGE OF MEDICINE. EACH YEAR, RECIPIENTS ARE SELECTED BY AN INDEPENDENT REVIEW PANEL OF ACADEMIC RESEARCHERS AND OPHTHALMOLOGISTS. THIS DISTINGUISHED PANEL AWARDS PROPOSALS THAT ENCOURAGE MEANINGFUL SCIENTIFIC INQUISITION AND ALIGN WITH EVERSIGHT'S MISSION TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH.

    Expenses $161,164 · Revenue $34,000

  • SUSTAINABLE INTERNATIONAL IMPACT IN 2022, EVERSIGHT PROVIDED TISSUE OR WORKED WITH SURGEONS IN 32 COUNTRIES TO PROVIDE THE GIFT OF SIGHT. EVERSIGHT IS FOCUSED ON MEETING THE HUMANITARIAN NEED FOR CORNEA TISSUES IN COUNTRIES WHERE SIGHT-RESTORING CORNEAL TRANSPLANT PROCEDURES WOULD OTHERWISE BE COMPLETELY UNAVAILABLE. THE BENEFICIARIES OF OUR SURGICAL TISSUE PROVISION AND COMMUNITY EYE BANK DEVELOPMENT INITIATIVES INCLUDE THE HUNDREDS OF THOUSANDS OF PEOPLE WHO SUFFER FROM EYE INJURIES AND BLINDING EYE DISEASES THAT CAN BE TREATED THROUGH CORNEAL TRANSPLANTATION, ALONG WITH THEIR FAMILIES AND LOCAL COMMUNITIES. ACCORDING TO THE WORLD HEALTH ORGANIZATION, EVERY DOLLAR SPENT ON IMPROVING EYE HEALTH IN UNDERDEVELOPED AREAS GENERATES A FOUR-FOLD RETURN ON INVESTMENT. TO ADDRESS SYSTEMIC UNMET NEED, EVERSIGHT ACTIVELY WORKS WITH MEDICAL PROFESSIONALS, GOVERNMENTS, VISION HEALTH ORGANIZATIONS AND OTHER NGOS IN REGIONS LACKING EYE BANKS AND INFRASTRUCTURE, INCLUDING THE MIDDLE EAST, PAKISTAN AND SOUTH KOREA. WITH PROVEN EYE BANKING AND TECHNICAL TRAINING PRACTICES-AND HAVING PLAYED A PART IN THE ELIMINATION OF THE U.S. CORNEA TRANSPLANT WAITING LIST-EVERSIGHT IS UNIQUELY QUALIFIED TO WORK WITH COUNTRIES LACKING TRANSPLANT PROGRAMS TO HELP THEM ESTABLISH NATIONAL NETWORKS FOR EYE BANKING AND CORNEA DONATION WITH CULTURALLY APPROPRIATE DONATION MODELS AND STATE-OF-THE-ART CLINICAL CAPABILITIES. NINETY PERCENT OF VISION-IMPAIRED PEOPLE LIVE IN LOW- AND MIDDLE- INCOME COUNTRIES. IN 2022, EVERSIGHT AND THE DEPARTMENT OF HEALTH - ABU DHABI (DOH), THE REGULATOR OF THE HEALTHCARE SECTOR IN THE EMIRATE, ANNOUNCED A PARTNERSHIP TO ESTABLISH THE FIRST EYE AND TISSUE BANK IN THE UNITED ARAB EMIRATES (UAE). THE PARTNERSHIP WAS FORMALIZED AT THE RECENT INTERNATIONAL CONFERENCE FOR INITIATIVES ON ORGAN AND TISSUE DONATION AND TRANSPLANTATION IN ABU DHABI. EVERSIGHT WILL HANDLE THE DEVELOPMENT AND IMPLEMENTATION OF COMPREHENSIVE MEDICAL STANDARDS, QUALITY ASSURANCE PROTOCOLS AND STANDARD OPERATING PROCEDURES IN COMPLIANCE WITH ALL LAWS AND REGULATIONS OF THE UAE AND IN ACCORDANCE WITH EYE BANKING BEST PRACTICES. THE DOH WILL BE RESPONSIBLE FOR OBTAINING ALL NECESSARY APPROVALS FOR THE ESTABLISHMENT AND OPERATION OF THE EYE AND TISSUE BANK, SERVING AS AN IMPORTER FOR CORNEAS AND OTHER EYE- RELATED TISSUES INTO THE REGION AND WORKING TO INTEGRATE THE EYE/TISSUE BANKING PROGRAM WITH THE UAE NATIONAL PROGRAM FOR ORGAN DONATION. THIS INITIATIVE WILL ALSO STRENGTHEN MUTUAL COLLABORATION IN ACTIVITIES RELATED TO KNOWLEDGE SHARING, HUMAN CAPABILITY BUILDING AND CLINICAL RESEARCH. GLOBALLY, AN ESTIMATED 2.2 BILLION PEOPLE ARE IMPACTED BY BLINDNESS AND VISUAL IMPAIRMENT. APPROXIMATELY ONE BILLION OF THESE INDIVIDUALS ARE COPING WITH BLINDNESS OR VISUAL IMPAIRMENT THAT CAN BE CHARACTERIZED AS PREVENTABLE OR NOT SUFFICIENTLY ADDRESSED. VISION LOSS RESULTS IN SUBSTANTIAL ECONOMIC IMPACT WORLDWIDE DUE TO THE INABILITY OF PEOPLE WHO ARE VISION IMPAIRED TO CONTRIBUTE TO THEIR FULLEST IN THEIR COMMUNITIES. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL PEOPLE IN EVERY COMMUNITY CAN LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. WHILE PROVIDING FOR IMMEDIATE GLOBAL CORNEA TRANSPLANT NEEDS WITH U.S. DONOR TISSUE, EVERSIGHT CONTINUES TO ADDRESS THE GLOBAL BURDEN BY EMPOWERING INTERNATIONAL COMMUNITIES TO TAKE MEANINGFUL, SUSTAINABLE STEPS EVERY DAY TO MAKE VISION A REALITY FOR ALL.

    Expenses $1,226,217 · Revenue $41,717

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Michael O'Keefe

    COO

    Total calculated
    $260,534
    From this org
    $206,161
    From related orgs
    $0
    Other
    $54,373
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $206,161
    Bonus
    not reported
    Other
    not reported
    Deferred
    $13,624
    Nontaxable benefits
    $40,749
    Filer's total
    $260,534
  • Julie Collins

    CFO

    Total calculated
    $263,203
    From this org
    $208,830
    From related orgs
    $0
    Other
    $54,373
    Hours/week
    50 + 7.5 related

    Schedule J breakdown matched by us

    Base
    $208,830
    Bonus
    not reported
    Other
    not reported
    Deferred
    $13,624
    Nontaxable benefits
    $40,749
    Filer's total
    $263,203
  • Michael Titus

    VP CLINICAL

    Total calculated
    $235,125
    From this org
    $181,082
    From related orgs
    $0
    Other
    $54,043
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $181,082
    Bonus
    not reported
    Other
    not reported
    Deferred
    $12,135
    Nontaxable benefits
    $41,908
    Filer's total
    $235,125
  • Diane Hollingsworth

    PRESIDENT &

    Total calculated
    $317,299
    From this org
    $254,972
    From related orgs
    $0
    Other
    $62,327
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $254,972
    Bonus
    not reported
    Other
    not reported
    Deferred
    $16,159
    Nontaxable benefits
    $46,168
    Filer's total
    $317,299
  • Bret Hopman

    VP MARKETING

    Total calculated
    $197,680
    From this org
    $151,755
    From related orgs
    $0
    Other
    $45,925
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $151,755
    Bonus
    not reported
    Other
    not reported
    Deferred
    $10,671
    Nontaxable benefits
    $35,254
    Filer's total
    $197,680
  • Patty Jo Herndon

    CHAIR

    Total calculated
    $0
    Hours/week
    1
  • Kathy L Zelenock

    VICE CHAIR

    Total calculated
    $0
    Hours/week
    1
  • Danielle E D'Arcy

    TREASURER

    Total calculated
    $0
    Hours/week
    1
  • Mahmoud N Ghazzi MD PhD

    SECRETARY

    Total calculated
    $0
    Hours/week
    1
  • Jarold Anderson

    IMM. PAST CH

    Total calculated
    $0
    Hours/week
    1
  • Lorenzo Cervantes MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Jonathan Lass MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Shahzad Mian MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Carol Cunningham MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Probi Kapur

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Carolyn M Welsh

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Catherine McClory

    DIR. COMPLIA

    Total calculated
    $178,534
    From this org
    $148,141
    From related orgs
    $0
    Other
    $30,393
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $148,141
    Bonus
    not reported
    Other
    not reported
    Deferred
    $9,061
    Nontaxable benefits
    $21,332
    Filer's total
    $178,534
  • Indu Vadakkepattath

    DATA SCI. &

    Total calculated
    $176,224
    From this org
    $144,969
    From related orgs
    $0
    Other
    $31,255
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $144,969
    Bonus
    not reported
    Other
    not reported
    Deferred
    $9,068
    Nontaxable benefits
    $22,187
    Filer's total
    $176,224
  • Andrea Medrano

    DIR. HUMAN R

    Total calculated
    $153,241
    From this org
    $129,153
    From related orgs
    $0
    Other
    $24,088
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $129,153
    Bonus
    not reported
    Other
    not reported
    Deferred
    $4,919
    Nontaxable benefits
    $19,169
    Filer's total
    $153,241
  • Onkar Sawant

    DIR. RESEARC

    Total calculated
    $180,738
    From this org
    $151,058
    From related orgs
    $0
    Other
    $29,680
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $151,058
    Bonus
    not reported
    Other
    not reported
    Deferred
    $9,154
    Nontaxable benefits
    $20,526
    Filer's total
    $180,738
  • Diana Budzynski

    CONTROLLER

    Total calculated
    $151,942
    From this org
    $117,117
    From related orgs
    $0
    Other
    $34,825
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $117,117
    Bonus
    not reported
    Other
    not reported
    Deferred
    $8,124
    Nontaxable benefits
    $26,701
    Filer's total
    $151,942

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

  • EVERSIGHT INTERNATIONAL

    3 · EYE BANK · MI · controlled entity

    Directly controlled by EVERSIGHT EVERSIGHT

  • EVERSIGHT NEW JERSEY

    3 · EYE BANK · NJ · controlled entity

    Directly controlled by EVERSIGHT EVERSIGHT

  • EVERSIGHT MICHIGAN

    3 · EYE BANK · MI · controlled entity

    Directly controlled by EVERSIGHT EVERSIGHT

  • EVERSIGHT ILLINOIS

    3 · EYE BANK · IL · controlled entity

    Directly controlled by EVERSIGHT EVERSIGHT

  • MIDWIRE SYSTEMS

    3 · SOFTWARE · MI · controlled entity

    Directly controlled by EVERSIGHT EVERSIGHT

  • EVERSIGHT OHIO

    3 · EYE BANK · OH · controlled entity

    Directly controlled by EVERSIGHT EVERSIGHT

  • EVERSIGHT CONNECTICUT

    3 · EYE BANK · CT · controlled entity

    Directly controlled by EVERSIGHT EVERSIGHT

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Related corporations and trusts

Part IV: related organizations taxable as a corporation or trust.

  • EVERSIGHT KOREA LLC

    C CORP · EYE BANK · KS

    Directly controlled by EVER INT EVERSIGHT INTERNATIONAL

Provenance

Return type
form_990
Tax year
2022
Filed
7 July 2023
IRS schema version
2022v5.0
Source object
202321939349300027

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.